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Open access under CC BYObjective: To examine the analytic role of arsenic exposure on cancer mortality among the low-dose (well
water arsenic level <150 lg/L) villages in the Blackfoot-disease (BFD) endemic area of southwest Taiwan
and with respect to the southwest regional data.
Method: Poisson analyses of the bladder and lung cancer deaths with respect to arsenic exposure (lg/kg/
day) for the low-dose (<150 lg/L) villages with exposure deﬁned by the village median, mean, or maxi-
mum and with or without regional data.
Results: Use of the village median well water arsenic level as the exposure metric introduced misclassi-
ﬁcation bias by including villages with levels >500 lg/L, but use of the village mean or the maximum did
not. Poisson analyses using mean or maximum arsenic levels showed signiﬁcant negative cancer slope
factors for models of bladder cancers and of bladder and lung cancers combined. Inclusion of the south-
west Taiwan regional data did not change the ﬁndings when the model contained an explanatory variable
for non-arsenic differences. A positive slope could only be generated by including the comparison popu-
lation as a separate data point with the assumption of zero arsenic exposure from drinking water and
eliminating the variable for non-arsenic risk factors.
Conclusion: The cancer rates are higher among the low-dose (<150 lg/L) villages in the BFD area than in
the southwest Taiwan region. However, among the low-dose villages in the BFD area, cancer risks suggest
a negative association with well water arsenic levels. Positive differences from regional data seem attrib-
utable to non-arsenic ecological factors.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Ingesting inorganic arsenic in drinking water is well recognized
as a cause of bladder and lung cancers in areas where arsenic expo-
sures exceed 500 lg/L (Cantor and Lubin, 2007). However, the typ-
ical exposure levels in the United States (US) have not historically
exceeded 150 lg/L. The epidemiological evidence is less clear at
the low to moderate concentrations (<150 lg/L) that have typically
been seen in the US (Nuckols et al., 2011). To assess the reduction
of carcinogenic risk that would be associated with the reduction of
levels in the US drinking water below the levels that had been typ-
ical, the risk must be based on data relevant to those US exposure
levels. Data sets that can assess the risk in that exposure range
(<150 lg/L) are few. The most commonly used data set for assess-treet, NW #615 Washington,
-NC-ND license.ing cancer risk from inorganic arsenic ingestion is the Wu et al.
(1989) cancer mortality study from the Blackfoot disease (BFD)-en-
demic area of southwest Taiwan. This data set has served as the ba-
sis in the US for the cancer risk analysis for the ingestion of
inorganic arsenic over the past decade, from the National Research
Council (NRC, 1999) to the US Environmental Protection Agency
(EPA, 2010). This data set is comprised of two clusters of villages,
one of which is comprised of villages with arsenic levels
<150 lg/L, and it is that subset that can be analyzed for the cancer
risk from arsenic levels of <150 lg/L.
The study population of the Wu et al. (1989) study is the adult
population of 42 villages in the BFD-endemic area of southwest
Taiwan whose cancer mortality was assessed for a 14-year period
(1973–1986) and for which the arsenic exposure has been summa-
rized as the village-speciﬁc median well water arsenic levels (lg/
L). While the villages in the study were selected in the late
1980s, the water arsenic data was from samples that had been col-
lected from the shallow and artesian wells that were still being
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vey. Two clusters are observed in the 1989 study – one with 18 low
arsenic exposure villages with median village arsenic levels rang-
ing between 10 and 126 lg/L and the other with 24 high arsenic
exposure villages with median village arsenic levels ranging be-
tween 256 and 934 lg/L. Signiﬁcantly elevated bladder and lung
cancer mortality have been clearly demonstrated for the villages
with arsenic levels in the hundreds of lg/L (Lamm et al., 2006).
Previous dose–response analyses have been published for the
entire set of 42 villages using either the age-adjusted mortality
rates (Chen et al., 1988; Wu et al., 1989), or standardized mortality
ratios with all Taiwan as the reference population (Morales et al.,
2000) or with standardized mortality ratios with southwest Tai-
wan as the reference population (Lamm et al., 2006). The Morales
et al. (2000) risk analysis, using the entire 42 village set, produced
a variety of risk analyses based on a generalized linear model or
multistage Weibull model using either no reference population
or either of the two reference populations.
Dose–response analyses for the low-dose villages are fewer.
Lamm et al. analyzed the village-speciﬁc standardized mortality
ratios (SMRs) and found either downward or level regressions
(Lamm et al., 2006, 2007). EPA analyzed the village-speciﬁc mortal-
ity data using Poisson regression analysis and found statistically
signiﬁcant positive (upward) regressions for each cancer outcome
(EPA, 2010). Both groups analyzed data on bladder and lung can-
cers using the data from the southwest region of Taiwan as a refer-
ence population, Lamm in an SMR analysis and EPA in a Poisson
analysis. EPA has also presented analyses using all-Taiwan as the
reference population. EPA has recommend that the ‘‘better way
to test the signiﬁcance of exposure–response relationships at low
doses is to simply restrict the analysis to the villages with low ar-
senic water concentrations but use the appropriate Poisson regres-
sion methodology’’ (EPA, 2010) (7, page F-6).
We now follow the EPA methodology and present here a Pois-
son regression analysis of bladder and lung cancer mortality for
the low-dose (<150 lg/L) villages with respect to the median,
mean, and maximum village well water arsenic levels. This paper
demonstrates the dependence of the EPA analyses on the compar-
ative differences in cancer risk of an external reference population
(southwest Taiwan) rather than on the distribution of well water
arsenic levels and cancer risks among the low-dose villages in
the Blackfoot disease endemic area.2. Materials and methods
The total dataset is comprised of demographic information (the
age-gender-speciﬁc person years of observation distributions for
1973–1986), outcome information (bladder and lung cancer deaths
distributions), and exposure information (well water arsenic mea-
surements or assumptions) for each of the 42 study villages in the
Wu et al. (1989) study as well as for two reference populations –
southwest region of Taiwan and all Taiwan- with the EPA assump-
tion that the water arsenic levels were zero for the reference pop-
ulations. The data, other than the age-distributions, were publicly
released as village-speciﬁc summary data in the NRC (1999) report
[Table A10-1]. The age-gender-stratiﬁed data for the reference
populations were published in Morales et al. (2000) and for the vil-
lages were publicly released by EPA in 2004.
Mortality information was obtained from death certiﬁcates for
the years 1973–1986 were collected for each village from the local
household registration ofﬁces of the studied townships and coded
for their underlying cause of death according to the Eighth Revision
of the International Classiﬁcation of Diseases (ICD-8). Mid-year
populations by age and sex for the studied villages were abstracted
from demographic reports of the local household registration ofﬁ-ces. Registration of in- and out-migration is mandatory in Taiwan,
as are registrations of births, deaths, marriages, and divorces.
Well water arsenic data had been abstracted from the 1964–
1966 survey (Kuo, 1968). The measurements had been made with
either the silver diethyldithiocarbamate method or the mercuric
bromide stain method (AWWA, 1955). These methods had stan-
dard deviations of 10 and 60 lg/L, respectively, for a synthetic
sample of 50 lg/L (AWWA, 1955). Wu et al. (1989) entered the
analyses based on the village medians and stratiﬁed with cut
points at 300 and 600 lg/L. The NRC (1999) table listed the well
water arsenic measurements for each village with the village medi-
ans. Village means and maxima could be developed from that list.
Arsenic exposure entered the analyses as daily dosage (lg/kg/
day) for the male and female adult (20+ years) population of each
village and area using the same exposure assumptions used by
EPA-non-water arsenic intake of 10 lg/day, drinking water con-
sumptions of 3.5 L/day for Taiwanese males and 2.0 L/day for Tai-
wanese females, and body weights of 50 kilogram for both
Taiwanese males and Taiwanese females. That is, arsenic dosage
for Taiwanese males was (10 lg/day + [3.5 L/day ⁄ As (lg/L)])/
50 kg/person) and for Taiwanese females was (10 lg/day + [2.0 L/
day ⁄ As (lg/L)]/50 kg/person).
Poisson regressions were conducted using the GEN MOD proce-
dure of SAS with village cancer mortality counts as the dependent
variable in a model with arsenic dosage as a linear parameter, age
as a quadratic parameter, and person-years of observation as an
offset variable. While there was some variation in age-distribution
between the study villages and the reference populations, there
was little variation in age-distribution among the study villages.
The models were ﬁt for males, females, and all, respectively. An ex-
act method was used when the model converged, and an approxi-
mation was used when the second derisive matrix (the Hessian
matrix) could not be inversed. The scale parameter was held ﬁxed.
The p-values were reported based on the 95% upper and lower con-
ﬁdence bounds.
The primary analysis related to the data for the 18 low-dose vil-
lages with median <150 ug/L. Subsequent analyses included the
southwest regional data and/or restricted the low-dose villages
to those with mean <150 ug/L or with maximum <150 ug/L. In
analyses including the regional data, an indicator area variable
was added to the analytic model in order to separate the differ-
ences in cancer risk factors for the study villages and those of the
regional data into those related to arsenic (and age) and those dif-
ferences not related to arsenic (and age). The indicator value for
area is ‘‘1’’ if the village is a study village in the Blackfoot-disease
endemic area and ‘‘0’’ if the area is not.3. Results
The basic data on population, exposure, and outcome for the 18
villages that comprise the low-dose villages, deﬁned as those with
median well arsenic levels less than 150 ug/L, are presented in Ta-
ble 1. The villages are numbered in ascending order by median well
water arsenic level as presented in the NRC (1999) report
[Table A10-1; pages 308–309]. The individual village’s identiﬁca-
tion numbers consisted of a numeral that represented the town-
ship number (0 I-chu; 2 Pu-tai; 3 Hsieh-chia; 4 Yen-shui; 5 Pei-
men; and 6 Hsia-ying) (Guo et al., 2007) and a letter that distin-
guished between the various villages within each township.
The dataset for the 18 villages included 123,569 male person-
years of observation and 112,827 female person-years of observa-
tion over the 14 year period 1973–1986 for an estimated total pop-
ulation of 16,885 adult residents. The estimated village
populations ranged between 363 and 1765 adults with an average
of 938 adults. The six-township area had 126 villages, only 42 of
Table 1
Population, exposure, and cancer Data for the 42 villages in the BFD-endemic area of southwestern Taiwan (Wu et al., 1989).
Population (Age 20–84) Arsenic Exposure Observed Outcome
Village Person-Years Adults Wells lg Arsenic per Liter Male Female Both
No. ID Male Female Pop. No. Pop/Well Median Mean Range Bladder Lung Bladder Lung All
1 3-H 4,159 4,043 586 1 586 10 10 – 1 3 6 5 15
2 2-I 3,529 3,194 480 1 480 11 11 – 0 0 0 1 1
3 0-G 5,388 4,861 732 5 146 30 216 10–770 3 4 2 5 14
4 3–5 7,851 7,033 1,063 1 1,063 32 32 – 3 6 3 2 14
5 3-N 2,689 2,392 363 1 363 32 32 – 4 3 3 1 11
6 4–7 10,629 10,227 1,490 1 1,490 42 42 – 0 0 0 0 0
7 6-A 7,716 6,820 1,038 1 1,038 45 45 – 0 0 0 0 0
8 0-J 6,501 5,888 885 2 442 50 50 20–80 1 0 0 0 1
9 3-L 6,238 5,094 809 2 405 56 56 53–58 3 5 4 7 19
10 4-D 10,107 9,227 1,381 1 1,381 60 60 – 1 1 2 1 5
11 3-P 6,574 5,927 893 1 893 65 65 – 0 2 0 5 7
12 6-C 12,767 11,937 1,765 1 1,765 73 73 – 0 2 1 0 3
13 4–8 11,307 10,332 1,546 1 1,546 80 80 – 1 2 0 2 5
14 0-O 6,895 6,392 949 1 949 100 100 – 0 3 0 1 4
15 0-E 5,753 5,310 790 5 158 110 236 10–686 6 4 3 5 18
16 0-I 4,249 3,833 577 7 82 110 236 20–590 0 3 2 2 7
17 4-N 4,709 4,291 643 2 321 123 123 73–172 0 1 0 2 3
18 4-J 6,508 6,026 895 1 895 126 126 – 0 2 1 2 5
Low-dose 123,569 112,827 16,885 35 482 73 144 10–770 23 41 27 41 132
SW Taiwan 14,689,807 12,862,006 1,967,987 –
All Taiwan 71,885,910 9,736,767 5,830,191 –
Fig. 1. Distribution of village arsenic exposure metrics (median, mean, and maximum) for the 18 villages with median <150 lg/L (Wu et al., 1989; NRC, 1999).
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14–18 of which were the low-dose villages. Thus, only 10–15% of
the BFD-endemic area villages were in these analyses. The remain-
der contributed to the southwest reference populations. The two
comparison or reference areas (southwest Taiwan and all Taiwan)
had adult populations of about two million and 10 million, respec-
tively. All populations have been truncated at <85 y/o.
The eighteen ‘‘low-dose’’ villages had measurements for a total
of 35 wells. The median concentration for these 35 wells was
73 lg/L and the mean was 144 lg/L. Fifteen of these villages had
measurements for only 1 or 2 wells; three had measurements on
5–7 wells. Two-thirds of the villages (12/18 = 67%) had a report
on only one well, and thus for these villages, their minimum, max-
imum, median, and mean arsenic levels were identical.
Of the three villages with measurements from two wells, the
paired measurements were quite similar in one village (53 and
58 lg/L) and dissimilar in the other two (20 and 80 lg/L; 73 and172 lg/L). That third village (N-4) had an elevated arsenic level
at 172 lg/L. Its maximum (172 lg/L) exceeded 150 lg/L, but its
mean (123 lg/L) and its median did not.
In contrast, each of the three villages that had measurements
from more than two wells (0-G, 0-E, 0-I) had at least one well with
a very high arsenic level (i.e., greater than 500 lg/L) of 590–
770 lg/L. The means (216, 236, and 236 lg/L) and maximums
(770, 686, and 590 lg/L) of these villages exceeded the low range
of <150 lg/L. Of the 18 ‘‘low-dose’’ villages with median arsenic le-
vel <150 lg/L, only ﬁfteen had a mean arsenic level <150 lg/L and
only fourteen had their maximum arsenic level at <150 lg/L. The
analytic set for the analyses by mean included the 15 villages with
mean <150 lg/L, and the analytic set for the analyses by maximum
included the 14 villages with maximum <150 lg/L.
US EPA (2010) assumed for each of the two reference popula-
tions (southwest Taiwan and all Taiwan) that the median and
mean drinking water arsenic levels were 0 lg/L. An early study
Fig. 3. Standardized mortality rates for bladder and lung cancers combined based
on southwest Taiwan and all-Taiwan reference populations by median village well
water arsenic level (lg/L).
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(Lewis et al., 2007) reported median arsenic levels of 30 and
380 lg/L, respectively, for shallow and artesian wells in the non-
endemic areas (Chen et al., 1962) and a later report (Chiang
et al., 1988) reported that 45–54% of wells in the non-endemic area
had arsenic content greater than 50 lg/L and 0–6% had levels
greater than 350 lg/L. The nation-wide survey in 1974–1976
reported that 5.7% of the wells outside of the BFD-endemic area
had arsenic levels of 50 lg/L or greater and that 0.3% had arsenic
levels greater than 350 lg/L (Lo et al., 1997).
Fig. 1 demonstrates that the analytic set of 18 villages with
median arsenic level <150 lg/L that EPA has described as ‘‘the vil-
lages with low arsenic wate concentrations’’ includes three villages
that have wells with arsenic levels >500 lg/L with an additional
village having a well with an arsenic kevel of 172 lg/L. Table 1
shows the range of measurements for these villages with their
median and mean levels as summary metrics. Wu et al. (1989)
had used the median village well water arsenic level as the metric
of central tendency and as the sole village-speciﬁc summary ar-
senic level. The arsenic levels used by Wu et al. (1989) had come
from the Kuo (1968) survey which had used the mean as the metric
of central tendency. The median has the advantage (or disadvan-
tage) that it is inﬂuenced by each of the well water measurements
rather than being dependent on only the central measure(s). The
mean and the maximum allow for the examination of the hypoth-
esis that the high exposure levels are critical. The median does not.
In total, the 18 villages with median <150 lg/L had 132 bladder
or lung cancer mortalities during 1973–1986, 64 in males and 68 in
females (Table 1). The per-village cancer death counts ranged be-
tween zero (villages 4–7 and 6-A) and 19 (village3-L). There were
23 male bladder cancer deaths in the 18 study villages and 27 fe-
male bladder cancer deaths. There were 41 male lung cancer
deaths and 41 female lung cancer deaths. While the numbers of
male and female cancer deaths were similar among the study vil-
lages, the numbers of male cancer deaths in the reference popula-
tions were about twice the number of female cancer deaths.
Further, while bladder cancers accounted for 38% of the bladder
and lung cancers combined counts for the villages, they accounted
for only 19% of those for the regional southwest Taiwan reference
population and 11% of those for the all Taiwan reference
population.
Table 1 presents the summarized data across all age 20–84 age
groups. The population (person years of observation) and outcome
(bladder and lung cancer deaths) data were made available by EPA
(2004) stratiﬁed by gender and age in ﬁve-year intervals (20–
84 years of age). Table 1 presents the data on the three summary
exposure metrics for the village arsenic levels in the EPA data setFig. 2. Bladder and lung cancer crude mortality rates for BFD-area v– the median, the mean, and the maximum. The exposure (village
well water arsenic levels) data were made available by NRC (1999)
and summarized as three summary exposure metrics for the indi-
vidual villages by EPA (2004) – the median, the mean, and the
maximum. The individual village well water arsenic data have
been published in NRC, 1999 report (Table A-10), and the three
summary exposure metrics are in Table 1. Fig. 1 graphically dem-
onstrates the medians, means, and maxima for the 18 low-dose vil-
lages. It is clear that the median values are insensitive to the very
high well water arsenic levels that were found in some of these vil-
lages. The analyses by means separates out the three villages with
the most markedly high levels (i.e., greater than 500 lg/L), and the
analyses by the maxima separates out the four villages that have
any well water level known to be greater than 150 lg/L.
The dose–response relationship between arsenic level and can-
cer risk can be examined using a variety of metrics of risk. The
most straight-forward metric is the crude mortality rate which is
the ratio of the number of cancer deaths divided by the number
of person-years of observation for each village. Fig. 2 shows the
distribution for the crude mortality rate for bladder and lung can-
cer combined for the eighteen low-dose villages. Simple linear
regression shows a downward slope that is not statistically signif-
icant (p = 0.40) and has little explanatory power (R2 = 0.045, or
4.5%).
Wu et al. (1989) presented cancer risks as age-adjusted mortal-
ity rates, standardized to the 1976 world population. A further
reﬁnement in the development of the risk metric, the standardized
mortality ratio, includes not only the age structure (distribution of
the person-years of observation) of the reference population butillages by median village well water arsenic level (<150 lg/L).
Table 2
Age-adjusted Poisson regression of cancer mortality on arsenic dosage (lg/kg/day) for
the 18 low-dose villages with median well water arsenic concentration <150 lg/L
(ppb). (Parentheses indicate negative co-efﬁcient; Bold indicates statistical signiﬁ-
cance with p<0.05).
Gender Cancer Arsenic 95% Conf. Int. p-value
Male Lung (0.0003) (0.0032) 0.0025 0.8155
Female Lung (0.0012) (0.0051) 0.0027 0.5394
Both Lung (0.0005) (0.0027) 0.0018 0.6831
Male Bladder (0.0023) (0.0064) 0.0017 0.2470
Female Bladder (0.0063) (0.0117) (0.0010) 0.0178
Both Bladder (0.0037) (0.0068) (0.0005) 0.0201
Male Combined (0.0010) (0.0034) 0.0013 0.3776
Female Combined (0.0031) (0.0063) (0.0000) 0.0471
Both Combined (0.0016) (0.0034) 0.0002 0.0791
Table 3
Age-adjusted Poisson regression of cancer mortality on arsenic dosage (lg/kg/day) for
the 15 low-dose villages with mean well water arsenic concentration <150 lg/L
(ppb). (Parentheses indicate negative co-efﬁcient; Bold indicates statistical signiﬁ-
cance with p<0.05).
Gender Cancer Arsenic 95% Conf. Int. p-value
Male Lung (0.0019) (0.0056) 0.0018 0.3041
Female Lung (0.0029) (0.0080) 0.0021 0.2452
Both Lung (0.0018) (0.0047) 0.0010 0.2020
Male Bladder (0.0092) (0.0016) (0.0027) 0.0047
Female Bladder (0.0134) (0.0208) (0.0060) 0.0003
Both Bladder (0.0107) (0.0156) (0.0059) 0.0000
Male Combined (0.0039) (0.0071) (0.0007) 0.0150
Female Combined (0.0067) (0.0109) (0.0025) 0.0013
Both Combined (0.0046) (0.0071) (0.0021) 0.0002
Table 4
Age-adjusted Poisson regression of cancer mortality on arsenic dosage (lg/kg/day) for
the 14 low-dose villages with maximum well water arsenic concentration <150 ug/L
(ppb). (Parentheses indicate negative co-efﬁcient; Bold indicates statistical signiﬁ-
cance with p<0.05).
Gender Cancer Arsenic 95% Conf. Int. p-value
Male Lung (0.0027) (0.0066) 0.0012 0.1711
Female Lung (0.005) (0.0106) 0.0006 0.0763
Both Lung (0.0028) (0.0059) 0.0003 0.0712
Male Bladder (0.0081) (0.0142) (0.0020) 0.0076
Female Bladder (0.0130) (0.0202) (0.0059) 0.0003
Both Bladder (0.0099) (0.0145) (0.0053) 0.0000
Male Combined (0.0044) (0.0077) (0.0011) 0.0080
Female Combined (0.0082) (0.0126) (0.0038) 0.0002
Both Combined (0.0053) (0.0079) (0.0027) 0.0000
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ulation. Fig. 3 presents the results of the standardized mortality ra-
tio analysis for bladder and lung cancer mortality for the eighteen
villages using either southwest Taiwan or all Taiwan as the refer-
ence population. The mortality rates for individual cancers in the
southwest region are different from those of the all Taiwan data
(from 15% lower for male lung cancers to 90% higher for female
bladder cancers), although both groups were assigned an arsenic
drinking water exposure of 0 ug/L. Nonetheless, there is little dif-
ference in the distributions of the SMRs for the cancers combined
between the two reference populations.
Linear regression analysis of the SMR data can be weighted by
the size of the population of each village. The analytic advantages
of the SMRs include that they account for the age distributions
within the villages, each village is separately compared with the
reference population, and they are weighted by the village popula-
tion. The disadvantage is that it assumes that the uncertainty of the
point estimate of the SMR is distributed normally, which may not
be certain when the numbers of cases are small. The Poisson anal-
ysis is a further analytic reﬁnement that accounts for the small
number of cases by assuming that their uncertainty follows a Pois-
son distribution.
Poisson regression models have been analyzed for the low-dos-
age villages for each cancer-gender group (male lung, male blad-
der, female lung, and female bladder) and their combinations
(males, females, lung, bladder, and all) using the median, mean,
or maximum village well water arsenic level as the summary expo-
sure metric.
Table 2 shows the results of the Poisson analyses for each of the
gender cancer groups and for each of the combined groups for the
18 low-dose (median < 150 ug/L) villages. All nine cancer endpoint
models show a negative dose–response. The slope is signiﬁcantly
negative for the female bladder cancer model (p = 0.0178) as well
as for the model of both female and male bladder cancers
(p = 0.0201) and the model for female bladder and female lung
combined (p = 0.0471). No statistically signiﬁcant association is
found for the male cancer deaths or for the female lung cancer
deaths. This ﬁnding indicates that for population groups with med-
ian well water arsenic concentrations <150 lg/L, the dose–re-
sponse relationships are negative and occasionally (3/9)
statistically signiﬁcantly negative.
The set of low dose villages based on the mean village well
water arsenic level being <150 lg/L is comprised of 15 of the pre-
vious 18 villages. Excluded from it are the three villages which
have well arsenic levels >500 lg/L (villages 0-G, 0-E, and 0-I in I
chi township) and have mean village well water arsenic level that
exceeds 200 lg/L. Table 3 presents the results of the Poisson anal-
yses the cancer data for the 15 low dose villages with mean village
well arsenic level <150 lg/L. The slope of each model is negative.
The slopes are statistically signiﬁcantly negative for the bladdercancer and combined cancer models but not for the lung cancer
models.
The villages with mean village well water arsenic level <150 lg/
L does include one village (4-N) with a well water measurement
greater than 150 lg/L. Redeﬁning low dosage villages or ‘‘villages
with (only) low arsenic water concentrations’’ as those with all
known exposures being <150 lg/L is accomplished by using as
the village exposure metric that the maximum well water arsenic
level is <150 lg/L. Table 4 presents the results of the Poisson anal-
yses for those 14 villages. The slope of each model is negative. As
with the analyses by the village mean, none of the lung cancer
slopes are statistically signiﬁcantly negative, while all the bladder
cancer and combined cancer slopes are.
EPA (2010) conducted the Poisson analyses using only the med-
ian as their village-speciﬁc summary metric of the arsenic expo-
sure, though they explored the use of the minimum and of the
maximum in their sensitivity analysis (pages 139–140). They dem-
onstrated that their use of the mean or of the maximum had a sub-
stantial (>20%) effect on the risk estimates. We have conducted the
Poisson analyses using three summary exposure metrics – the
median, the mean, and the maximum. Poisson analyses are pre-
sented for the villages with low arsenic concentrations (median
<150 lg/L) in Table 2, for the villages with low arsenic concentra-
tions (mean <150 lg/L) in Table 3, and for the villages with low ar-
senic concentrations (maximum <150 lg/L) in Table 4.
The Poisson analyses of the ‘‘low-dose’’ village cancer mortality
reach similar and consistent ﬁndings, whether based on the med-
ian, the mean, or the maximum for the villages. In all cases, the
cancer slopes with a range up to 150 lg/L are negative with respect
to the arsenic level. Tables 2–4 demonstrate in the Poisson analy-
ses that as the deﬁnition of low dose arsenic is tightened, the num-
ber of models with a statistically signiﬁcant negative slope
increases. Previous analysis based on standardized mortality ratios
(SMRs) have also demonstrated negative slopes at low exposures.
Table 5
Age-adjusted Poisson regression of cancer mortality on arsenic dosage (lg/kg/day) for
the 18 low-dose villages with median well water arsenic concentration <150 lg/L
(ppb), including southwest Taiwan regional data as a 19th Village. (Bold indicates
statistical signiﬁcance with p<0.05).
Gender Cancer Arsenic 95% Conf. Int. p-value
Male Lung 0.0014 0.0002 0.0026 0.0245
Female Lung 0.0045 0.0029 0.0061 0.0000
Both Lung 0.0024 0.0014 0.0034 0.0000
Male Bladder 0.0070 0.0024 0.0056 0.0000
Female Bladder 0.0071 0.0049 0.0093 0.0000
Both Bladder 0.0051 0.0038 0.0064 0.0000
Male Combined 0.0020 0.0011 0.0030 0.0000
Female Combined 0.0035 0.0039 0.0066 0.0000
Both Combined 0.0031 0.0024 0.0039 0.0000
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10–50 lg/L for bladder cancer mortality in both CMR and SMR
analyses. Lamm et al., 2006 showed for low-dose villages a nonsig-
niﬁcant negative dose response for bladder and lung cancer SMR.
Thus, the dose–response results based on the low-dose village data
and presented as SMR or Poisson analyses are similar with negative
slopes, some of which reach statistical signiﬁcance, particularly
those that include female bladder cancers.
The Poisson analyses in Tables 2–4 have been limited to the
data for the 14–18 low-dose villages in the study area. The Poisson
analyses in Tables 5 and 6 include also the data for the southwest
region of Taiwan as an additional ‘‘village’’ and the EPA-assumed
drinking water exposure metric of 0 lg/L. Table 5 includes ‘‘19 vil-
lages’’ in the analysis, which are the 18 villages with median
<150 lg/L plus the southwest region, using the southwest region
data as if it were a 19th low-dose village. This Poisson analysis is
analogous to that of Table F-2 in EPA (2010; page F-6). These re-
sults similarly indicate that ‘‘the arsenic dose coefﬁcients are posi-
tive with lower conﬁdence limits that are also positive’’ and that
‘‘the dose–response relationships are positive and statistically
signiﬁcant.’’
Table 6 presents alternatively an extension of the Poisson anal-
ysis in Table 5 with the contribution from the southwest regional
data contributing both as an arsenic-related component and as a
non-arsenic-related (area) component. The arsenic-related slopeTable 7
Comparison of cancer risks (Rate = Deaths/1000 PYRS) for high-dose villages (mean and m
wells) and low-dose villages without high wells (low-dose) versus reference populations
Villages Mean Median Villages PYRs Lung cancer Bladd
High Dose >150 > 150 24 254,533 184 125
High Wells >150 < 150 3 29,394 23 16
Low Dose <150 < 150 15 207,002 59 34
SW Taiwan – – – 27,552,085 4,621 1,050
All-Taiwan – – – 136,314,736 25,895 3,199
Table 6
Age-adjusted Poisson regression of cancer mortality on arsenic dosage (lg/kg/day) for the
including southwest Taiwan regional data as a 19th village and an area variable for study a
with p<0.05).
Gender Cancer Arsenic 95% Conf. Int.
Male Lung (0.0003) (0.0032) 0.0025
Female Lung (0.0012) (0.0052) 0.0027
Both Lung (0.0005) (0.0027) 0.0018
Male Bladder (0.0023) (0.0064) 0.0017
Female Bladder (0.0064) (0.0117) (0.0010)
Both Bladder (0.0037) (0.0068) (0.0005)
Male Combined (0.0010) (0.0034) 0.0013
Female Combined (0.0031) (0.0063) (0.0000)
Both Combined (0.0016) (0.0034) 0.0002factors are all negative, with some statistically signiﬁcantly nega-
tive. None of the slopes for the models limited to lung cancers have
statistically signiﬁcant slopes, nor do most of those containing
male bladder cancers. However, most of the models containing fe-
male bladder cancers have slopes that are statistically signiﬁcantly
negative.
In contrast, the area slope factor, or non-arsenic-related slope
factor, in Table 6 is strongly statistically signiﬁcantly positive in
all models except for that of the male lung cancers. The strongly
statistically signiﬁcantly positive contribution to the slope factor
by the southwest regional data is seen to come from the non-ar-
senic related (area) component and not to be related to the arsenic
related cancer slope factor. The arsenic-related cancer slope factors
in Table 6 are essentially identical to the arsenic-related cancer
slope factors in Table 2. The non-arsenic-related (or area) slope fac-
tors seem to mimic the ﬁndings in our Table 5 and EPA’s Table F-6.
This analytic reﬁnement has separated the arsenic-related inﬂu-
ence from the non-arsenic-related (area) inﬂuence that the inclu-
sion of the southwest regional data as an additional data point
has brought into the analysis.
In Table 7, we have separated the 42 villages in the six-town-
ship BFD-endemic area that have known well water arsenic levels
into three groups – the 24 high exposure villages (median and
mean exceed 150 lg/L), the 3 low exposure villages with very high
level arsenic water (mean but not median exceeds 150 lg/L), and
the 15 low exposure villages without very high arsenic levels
(neither median nor mean exceed 150 lg/L). All three villages
in the middle group include well arsenic levels that exceed
500 lg/L, with maximum recorded levels of 590, 686, and
770 lg/L.
Table 7 shows the crude mortality rates for bladder and lung
cancers (and combined) for the three groups of villages and the
two reference populations (southwest Taiwan and all Taiwan).
The rates for the two reference populations are similar. The rates
for the low-dose villages (median and mean <150 lg/L) are about
twice that. The rates for high exposure villages, whether high-dose
villages or low-dose villages with high well arsenic levels, are also
similar. They are about three times as high as the low-dose, low-
exposure villages and six times as high as the reference
populations.edian >150 lg/L) with low-dose villages having wells with arsenic >150 lg/L (high
of southwest Taiwan and of all-Taiwan.
er Cancer Combined cancers Lung Rate Bladder rate Combined rate
309 0.72 0.49 1.21
39 0.78 0.54 1.33
93 0.29 0.16 0.45
5,671 0.17 0.04 0.21
29,094 0.19 0.02 0.21
18 low-dose villages with median well water arsenic concentration <150 lg/L (ppb),
rea. (Parentheses indicate negative co-efﬁcient; Bold indicates statistical signiﬁcance
p-value Area 95% Conf. Int. p-value
0.8137 0.4906 (0.2302) 1.2114 0.1734
0.5301 1.2403 0.5407 1.9399 0.0004
0.6751 0.7460 0.2643 1.2278 0.0020
0.2451 1.8640 0.9374 2.7907 0.0001
0.0172 2.8452 2.0458 3.6445 0.0000
0.0198 2.2677 1.6753 2.8600 0.0000
0.3746 0.8929 0.3250 1.4608 0.0017
0.0463 1.7931 1.2675 2.3187 0.0000
0.0766 1.2234 0.8503 1.5965 0.0000
Fig. 4. Cancer slope factor by cancer and by exposure metric for low-dose (<150 ug/L) villages in BFD-Area (Wu et al., 1989; Morales et al., 2000).
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senic levels have cancer risks that are consistent with those of
the high-dose villages rather than those of the low-dose villages.
Table 7 thus also demonstrates an exposure misclassiﬁcation bias
in the low-dose analyses that are based solely on the median vil-
lage well arsenic level, a bias that is corrected by use of the mean
or the maximum.
All analyses have assumed that the well measurements are
complete and representative. While there is no speciﬁc evidence
to the contrary, Table 1 has shown for the low-dose villages that
two-thirds of the villages have measurements for only one well
and that the number of villagers per well ranges from about 80
to 1800 – a range to suggest that not all water sources have been
identiﬁed. The risk pattern based on the villages with measure-
ments from only one well is accentuated compared to those with
multiple wells. Further, there is no information on the distribution
of well usage in multi-well villages or whether villagers used wells
from other villages, which may explain some of the variability in
risk.
Fig. 4 graphically presents the full set of cancer slope factor cal-
culations for lung, bladder, and lung and bladder cancers combined
and for males, females, and both using the ﬁve data sets analyzed
above – the 18 villages with median <150 lg/L, the 15 villages with
mean <150 lg/L, the 14 villages with maximum <150 lg/L, the 19
‘‘villages’ which includes the southwest Taiwan population as the
19th village, and the 19 ‘‘village’’ including the area variable. The
graph demonstrates that, with the exception of the 19 ‘‘village’’
analyses, all the cancer slope factors are negative. It is only the
19 ‘‘village’’ analysis that EPA (2010) used that uniquely yields po-
sitive cancer slope factors.
4. Discussion
Poisson analysis of the bladder and lung cancer mortality data
of the low arsenic exposure (<150 lg/L) villages in the Wu et al.
(1989) study in the BFD-endemic area of southwest Taiwan consis-
tently yields negative slopes (arsenic ‘‘b’’ coefﬁcient; cancer slope
factor [CSF]) whether exposure is deﬁned on the basis of the med-
ian, mean, or maximum village well water arsenic level being
<150 lg/L. When based on the village medians, the slopes are sta-
tistically signiﬁcantly negative for most of the models containing
female bladder cancers. Further, when based on the mean or the
maximum village well water arsenic level, the slopes are statisti-
cally signiﬁcantly negative for the bladder cancer or lung and blad-
der cancer models but not for the models that only contain lung
cancers.There are a number of ways in which our analyses differ from
those of EPA (2010), in addition to the inclusion of analyses based
on the village means and the village maxima. Some of the differ-
ences yield a shift in frame where the units are different but nei-
ther the pattern nor the statistical signiﬁcance is different. The
EPA model was developed for the purpose of using the Taiwan data
to estimate the risks from arsenic in drinking water for US popula-
tions – as stated, ‘‘this risk assessment assumes that the observed
carcinogenic potency in the Taiwanese population, with suitable
corrections for differences in drinking water intake and back-
ground cancer incidence, is an appropriate predictor of the poten-
tial for human cancer risk in the US population.’’ (EPA, 2010) (7;
page 152) They furthered their analysis for US populations by con-
verting from mortality risks to incidence risks using BEIR IV mod-
eling and assuming that the male and female US populations had a
mean body weight of 70 kilograms and an average daily water con-
sumption of 2 L/day (EPA, 2010 (Page 139; Table 5–10). Their anal-
ysis presented arsenic levels as ppm rather than as ppb (lg/L), but
that too would only affect the decimal point and not the statistical
ﬁndings.
Other differences affect the nature of the association as a conse-
quence of unstated assumptions. The primary difference between
our analyses and that of EPA (2010) is that their analysis included
the data from the southwest region of Taiwan as if it were an addi-
tional or ‘‘19th’’ low-dose village and has assigned the regional
data a drinking water arsenic concentration of 0 lg/L. Their analy-
sis was limited to the use of the median as the measure of central
tendency. Table 5 is our replicate of their analysis for the low-dose
villages as it relates to the Taiwanese population (EPA, 2010) (7,
Table F-2). This ﬁnding is limited to the analysis based on the med-
ian. The same analysis based on either the mean or the maximum
show positive slopes that are not statistically signiﬁcant for the
male cancers (lung, bladder, or both).
The results of Table 5 are consistent with EPA interpretation of
its own results, that is, ‘‘For all of the endpoints, the arsenic dose
coefﬁcients are positive with lower conﬁdence limits that are also
positive. This ﬁnding indicates that for population groups with
water arsenic concentrations less than or equal to 126 ppb [lg/
L], the dose–response relationships are positive and statistically
signiﬁcant.’’ (page F6) The 18 villages that EPA groups as those
with median <126 lg/L are the same 18 villages that we group as
those with median <150 lg/L.
An underlying, and unstated, assumption in the ‘‘19 village’’
model is that the only explanatory factor accounting for bladder
and lung cancer distribution between the study villages and the
southwest region is the drinking water arsenic concentration. This
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disadvantage, however, of using an external comparison group is
that the analysis can be biased if the study population differs from
the comparison population in important ways’’ (Page 190).
Fig. 3 demonstrated that the SMRs differed little, whether based
on the southwest regional data or the all Taiwan data, thus sug-
gesting that the background risks in the two reference populations
differed little. Both reference populations in the analyses included
both urban populations in the cities and rural populations in the
counties. In contrast, the BFD-endemic area was strictly a rural
population that by Taiwanese standards was nutritionally and
socioeconomically depressed (Yang and Blackwell, 1960). Both
have been reported to be risk factors for arsenic-related diseases
(Ch’I and Blackwell, 1968; Chen, 2001). The carbohydrate source
in the diet was sweet potatoes rather than rice, and samples of
dried sweet potatoes from the BFD-endemic area showed a mean
arsenic level of 0.180 mg/kg (Blackwell et al., 1961). The associa-
tion between poor nutritional status and arsenicosis had been
shown in Bangladesh (Milton et al., 2004). Table 6 presents an
analysis that tests the assumption that there are no other factors
differentiating the study villages and the regional data that inﬂu-
ences the cancer risks other than age and median arsenic concen-
tration. The same analyses have been done based on the village
means and on the village maxima and yield analogous results.
The negative arsenic slopes are statistically signiﬁcant for all 12
models containing bladder cancers but only for one of the six mod-
els restricted to lung cancers [see Supplemental tables].
This comparison demonstrates that the differences in risks be-
tween the study villages and the comparison areas are signiﬁcant
and are not explained by their differences in arsenic exposure.
The positive slopes in Table 5 thus appear to be a consequence of
non-arsenic related aspects of the comparison area. Table 6 dem-
onstrates the effect of non-arsenic related factors that distinguish
the bladder and lung cancer risks in the Blackfoot disease (BFD) en-
demic parts of the southwest region from risks in the non-BFD en-
demic parts of the southwest region. The basis for this residual
difference in risk is neither known nor demonstrated. Whether
the area differences in cancer risk can be explained by the use of
the artesian wells, by the organic substances in the well water,
or from other aspects of the differences in the areas cannot be
ascertained from these data.
The ﬁrst clearly known difference is the presence of Blackfoot
disease in the study area and its absence in the comparison area.
The second clearly known difference is the markedly lower educa-
tion and socio-economic status of the villagers in the BFD area
compared with the general and urban populations of Taiwan, and
the third is that their diets had insufﬁcient amounts of fresh vege-
tables and animal protein (Tsai et al., 1999). Unlike the local refer-
ence population in the Tsai et al. (1999) study which was limited to
Tainan and Chia-Yi counties, the southwest Taiwan reference pop-
ulation used in the Morales et al. (2000) analysis of the Wu et al.
(1989) study included the populations of Tainan and Chia-Yi cities
in addition to the populations of the counties. The urban (city) pop-
ulations made up 37% of the southwest Taiwan population. The ef-
fects of the social and economic differences between the cities and
the counties are reﬂected in the life expectancies with the life
expectancies in these two cities being more than a year greater
than the life expectancies in these two counties (Taiwan Ministry
of Interior, 2012).
Blackfoot disease has been uniquely found in the BFD-endemic
area of southwest Taiwan and not elsewhere in the world. The
wells in I-Lan county in northeast Taiwan have the same levels
of arsenic as found in the BFD-endemic area of southwest Taiwan
and the duration of drinking from the wells is similar, yet BFD is
not a disease of I-Lan county Chen et al. (1995). Further, endemic
BFD has not been reported from the high arsenic areas in India,China, Mexico, Argentina, or Chile, particularly from Antofagasto,
Chile where the drinking water arsenic levels were as high as
860 lg/L for thirteen years. Secondly, Blackfoot disease has been
speciﬁcally associated only with the high arsenic artesian well
waters in the endemic area (Chen et al., 1962). Thirdly, bladder
cancer incidence in the Blackfoot disease endemic area has been
speciﬁcally associated with elevated levels of humic acids found
in the artesian well waters of the area Lu et al., 1986).
The early epidemiological studies of Chen et al. (1962) demon-
strated that the BFD-endemic area had both a shallow aquifer ob-
tained by a hand pump and a deep aquifer obtained by artesian
wells and that BFD occurred only in the villages that had artesian
wells. Chen et al. (1962) demonstrated that the waters of the arte-
sian wells differed from those of the shallow wells primarily by
high arsenic levels and secondarily by both algae and high iron
content. Lu et al. (1986) demonstrated that the artesian waters
green ﬂuorescent substances, later summarized as humic acid,
was associated with bladder cancer incidence. Chen et al. (1985)
showed the bladder and lung cancer mortality in the BFD-endemic
area to be associated with BFD-endemicity at the village and town-
ship level and to the use of artesian wells. Chen et al. (1986) related
cancer risk to the duration of artesian well use, and Lu et al. (1986)
related cancer risk to the speciﬁc presence of humic or ﬂuorescent
substances. Further, additional studies or analyses showed that
BFD (which is uniquely found here) is a known risk factor for the
skin cancers (Tseng et al., 1968) and for the bladder cancers
(Chiang et al., 1988), or that the dose–response patterns for blad-
der and lung cancers here are consistent with a threshold model
at about 150 lg/L (Lamm et al., 2006, 2007). These are all factors
which differentiate the BFD-endemic area from the non-BFD ende-
mic areas of southwest Taiwan.
The inclusion of the southwest regional data could affect the
analysis both because of its size and because of its values. The
southwest region has a population of 1.97 million persons and con-
tributes 27.6 million person years of observation. It is more than
2000 times greater than the average village (935 persons and
13,089 person-years of observation). It is an over-inﬂuential data
point as it has 98% of the bladder and lung cancer deaths and
99% of the adult population and person-years in this analysis. Mod-
eling indicates that the major inﬂuence of the southwest data is
from its size rather than its values. The regional data is the ele-
phant in the dataset, and the village data are the tail.
The bladder and lung cancer risks in the BFD-endemic area have
been shown in Chen et al. (1985) to be elevated above that of Tai-
wan with SMRs for lung cancers that are elevated by a factor of 4
and for bladder cancers by a factor of 10–20. The population-
weighted median drinking water arsenic level for the low-dose vil-
lages was found to be 66 lg/L. There was no positive trend among
the low-dose villages themselves. The southwest region was as-
signed a drinking water arsenic level of 0 ug/L. Clearly any analysis
would show a positive slope between the two areas, even without
considering the exposure distribution among the study villages.
The critical question is the dose–response or risk relationship for
differences in arsenic exposure among the low -ose villages.5. International perspective
The ﬁrst report of arsenic content of drinking water in the
Blackfoot-disease endemic area was summarized as a mean of
0.59 mg/L (590 lg/L) for 13 deep well samples in Blackwell et al.
(1961) and later as a mean of 0.52 mg/L (520 lg/L) for 126 artesian
well samples in Kuo (1968). Other reports from the BFD-area used
the median (Chen et al., 1962; Wu et al., 1989), as has EPA in its
toxicological reviews (EPA, 2010). Elsewhere, the mean has been
widely used to summarize arsenic exposure from drinking water.
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wan (Kuo, 1968), Argentina (Hopenhayn-Rich et al., 1996), USA
(Bates et al., 1995, 2004; Steinmaus et al., 2003; Meliker et al.,
2010), Denmark (Baalstrop et al., 2008), Taiwan (Guo, 2004), and
in tox studies from USA (Vig et al., 1984; Warner et al., 1994;
Moore et al., 1996), Inner Mongolia (Fujino et al., 2005), Bangla-
desh (Argos et al., 2006), India (De Chaudhuri et al., 2006; Ghosh
et al., 2006), Mexico (Gonsebatt et al., 1997).
The results of the Poisson analyses of these data are unique in
ﬁnding statistically signiﬁcant negative slopes in the low-dose
range (<150 lg/L). However, they are consistent with the rest of
the literature in not ﬁnding signiﬁcant positive slopes in the expo-
sure range below 100–200 lg/L. No association between bladder
cancer and low arsenic exposures was found either in multiple
case-control studies from multiple areas – Utah (Bates et al.,
1995), Finland (Kurttio et al., 1999; Michaud et al., 2004) Califor-
nia/Nevada (Steinmaus et al., 2003), Argentina (Bates et al.,
2004), New Hampshire (Karagas et al., 2004), and Michigan (Meli-
ker et al., 2010), or in cohort or ecological studies from multiple
areas – Utah (Lewis et al. 1999), southwest Taiwan (Guo and Tseng,
2000), USA (Lamm et al. 2004), Denmark Baalstrop et al. 2008), and
northeast Taiwan (Chen et al., 2010b). The Mink et al., 2008 meta-
analysis of epidemiological studies of low-level arsenic exposure in
drinking water and bladder cancer concluded that arsenic expo-
sure did not appear to be a signiﬁcant independent risk factor of
bladder cancer, though smoking was a possible effect modiﬁer
(Mink et al., 2008). Similarly, no association between lung cancer
and low arsenic exposures was found in cohort or ecological stud-
ies – Utah (Lewis et al. 1999), southwest Taiwan (Guo, 2004), Den-
mark (Baalstrop et al., 2008), Bangladesh (Mostafa et al., 2008),
New Hampshire/Vermont (Heck et al., 2009), and northeastern Tai-
wan, (Chen et al., 2010a). These analyses of the data from the
Blackfoot-disease endemic area of southwest Taiwan show nega-
tive associations for bladder cancer and for bladder and lung can-
cers combined and low arsenic exposures in any of the analyses
based on the low-dose (<150 ug/L) village data unless the south-
west Taiwan population is entered as an additional village.
These analyses have demonstrated that the village exposure can
be summarized as a median, a mean, or a maximum value. The use
of the mean or the maximum value has eliminated exposure mis-
classiﬁcation introduced by the median and with it the inclusion of
villages with wells containing >500 lg/L arsenic. Thus, in this case,
the use of the mean or the maximum has the advantage of using
cleaner data. Further, if the results are to be used in risk analysis
or for regulatory purposes, the mean and the maximum have the
advantage that they can be used to describe other populations.
The median is not a useful metric for describing exposures for reg-
ulated populations.
Fig. 4 graphically presents the full set of cancer slope factor cal-
culations for lung, bladder, and lung and bladder cancers combined
and for males, females, and both using the ﬁve data sets analyzed
above – the 18 villages with median <150 lg/L, the 15 villages with
mean <150 lg/L, the 14 villages with maximum <150 lg/L, the 19
‘‘villages’ which includes the southwest Taiwan population as the
19th village, and the 19 ‘‘village’’ including the area variable. The
graph demonstrates that, with the exception of the 19 ‘‘village’’
analyses, all the cancer slope factors are negative. It is only the
19 ‘‘village’’ analysis that EPA (2010) used that uniquely yields po-
sitive cancer slope factors.6. Conclusion
The bladder and lung cancer mortality data from the 18 ‘‘low-
dose’’ villages in the Blackfoot-disease endemic area of southwest
Taiwan that are from the Wu et al. (1989) study have been ana-lyzed, initially based on median <150 lg/L, then on mean
<150 lg/L and then on maximum <150 lg/L. Simple linear regres-
sion (or population-weighted) linear regression of the crude mor-
tality rates and of the standardized mortality ratios (with respect
to either southwest Taiwan or all Taiwan) yielded negative or
non-positive slopes. Poisson regression of the mortality distribu-
tions based on village medians showed only negative slopes, some
of which, mostly those including female bladder cancers, were sta-
tistically signiﬁcantly negative. Use of the mean or maximum as
the exposure metric eliminated confounding from villages with
very high (>500 lg/L) well water arsenic levels. Poisson analyses
based on the use of the mean or the maximum levels were statis-
tically signiﬁcantly negative for bladder cancer models and for
models with bladder and lung cancers combined. Extension of
the analytic population to include southwest regional data simi-
larly demonstrated statistically signiﬁcantly negative slopes for ar-
senic levels when the models included a variable for non-arsenic
area factors. Signiﬁcant positive slopes could only be obtained
when models assumed that all differences between areas could
only be attributed to arsenic exposure levels.Conﬂict of interest
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